

moisture, pH, residue on ignition, identity, and crystallinity.

(b) The batch, for potency, pH, and loss on drying.

(ii) Samples required:

(a) The erythromycin ethylsuccinate used in making the batch: 10 containers each consisting of approximately 500 milligrams.

(b) The batch: A minimum of 6 immediate containers.

(b) *Tests and methods of assay*—(1) *Potency*. Proceed as directed in § 436.105 of this chapter, preparing the sample for assay as follows: Reconstitute as directed in the labeling. Place an accurately measured representative portion of the sample into a high-speed glass blender jar containing sufficient methyl alcohol to give a final volume of 200 milliliters. Blend for 3 to 5 minutes. Further dilute an aliquot with 0.1M potassium phosphate buffer, pH 8.0 (solution 3), to the reference concentration of 1.0 microgram of erythromycin base per milliliter (estimated).

(2) *pH*. Proceed as directed in § 436.202 of this chapter, using the suspension prepared as directed in the labeling. If the suspension contains 80 milligrams per milliliter, equilibrium usually is reached in approximately 15 minutes.

(3) *Loss on drying*. Proceed as directed in § 436.200(b) of this chapter.

[39 FR 19149, May 30, 1974, as amended at 47 FR 21240, May 18, 1982; 50 FR 19921, May 13, 1985]

**§ 452.125d Erythromycin ethylsuccinate tablets.**

(a) *Requirements for certification*—(1) *Standards of identity, strength, quality, and purity*.

Erythromycin ethylsuccinate tablets are composed of erythromycin ethylsuccinate and suitable and harmless diluents, binders, buffers, and colorings. Each tablet contains erythromycin ethylsuccinate equivalent to 400 milligrams of erythromycin. Its potency is satisfactory if it is not less than 90 percent and not more than 120 percent of the number of milligrams of erythromycin that it is represented to contain. The loss on drying is not more than 4.0 percent. The tablets shall disintegrate within 40 minutes. The erythromycin ethylsuccinate used conforms to the standards prescribed by § 452.25(a)(1).

(2) *Labeling*. It shall be labeled in accordance with the requirements of § 432.5 of this chapter.

(3) *Requests for certification; samples*. In addition to complying with the requirements of § 431.1 of this chapter, each such request shall contain:

(i) Results of tests and assays on:

(a) The erythromycin ethylsuccinate used in making the batch for potency, moisture, pH, residue on ignition, identity, and crystallinity.

(b) The batch for potency, loss on drying, and disintegration time.

(ii) Samples required:

(a) The erythromycin ethylsuccinate used in making the batch: 10 packages, each containing approximately 500 milligrams.

(b) The batch: A minimum of 36 tablets.

(b) *Tests and methods of assay*—(1) *Potency*. Proceed as directed in § 436.105 of this chapter, preparing the sample for assay as follows: Place a representative number of tablets into a high-speed glass blender jar containing sufficient methyl alcohol to yield a concentration of 5 milligrams of erythromycin activity or less per milliliter when blended. Blend for 3 to 5 minutes. Further dilute an aliquot of this solution with 0.1M potassium phosphate buffer, pH 8.0 (solution 3), to the reference concentration of 1.0 microgram of erythromycin base per milliliter (estimated).

(2) *Loss on drying*. Proceed as directed in § 436.200(a) of this chapter.

(3) *Disintegration time*—(i) *If the tablet is uncoated*. Proceed as directed in § 436.212 of this chapter, using the procedure described in paragraph (e)(1) of that section.

(ii) *If the tablet is plain-coated*. Proceed as directed in § 436.212 of this chapter, using the procedure described in paragraph (e)(2) of that section.

[41 FR 51596, Nov. 23, 1976, as amended at 50 FR 19921, May 13, 1985; 55 FR 14091, Apr. 16, 1990]

**§ 452.125e Erythromycin ethylsuccinate-sulfisoxazole acetyl for oral suspension.**

(a) *Requirements for certification*—(1) *Standards of identity, strength, quality, and purity*.

Erythromycin ethylsuccinate-sulfisoxazole acetyl for